OPTH and OPTI Related Headlines

Go Back

Jun 29, 2026 11:37AM Optimi Health ships psilocybin capsules to Australia in third export
Jun 29, 2026 11:13AM Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Jun 29, 2026 09:01AM Optimi Health ships psilocybin capsules to Australia in third export
Jun 29, 2026 09:00AM Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Jun 16, 2026 12:36PM Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Jun 16, 2026 08:33AM OPTIMI Health adds 1mg and 2mg psilocybin doses for clinical research
Jun 16, 2026 08:30AM Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Jun 10, 2026 02:25PM Optimi Health exports psilocybin to UK for phase 2 clinical trial
Jun 10, 2026 02:25PM Optimi Health ships first psilocybin export to UK for phase 2 trial
Jun 10, 2026 02:25PM Optimi Health exports psilocybin to UK for phase 2 clinical trial
Jun 10, 2026 02:24PM Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Jun 8, 2026 12:54PM Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
May 29, 2026 11:16AM Australia expands psychedelic therapy access with updated prescriber rules
May 29, 2026 11:14AM Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
May 20, 2026 11:30AM Optimi Health prices $15 million offering, lists on NASDAQ
May 20, 2026 11:30AM Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

OPTH and OPTI Related Press Releases

Go Back

Jun 29, 2026 11:13AM Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Jun 29, 2026 09:00AM Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Jun 16, 2026 12:36PM Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Jun 16, 2026 08:30AM Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Jun 10, 2026 02:24PM Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Jun 8, 2026 12:54PM Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
May 29, 2026 11:14AM Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
May 20, 2026 11:30AM Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

OPTH and OPTI Related SEC Filings

Go Back